Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Hormone-sensitive Prostate Cancer (mHSPC)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT06446401
What this trial is testing

The Case of "Triple" Versus "Double" Therapy for Patients With High Volume Metastatic Hormone Sensitive Prostate Cancer

Who this might be right for
Prostate Cancer
Uppsala University 1,400
Early research (Phase 1)Active Not RecruitingNCT06193993
What this trial is testing

Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients

Who this might be right for
Prostate CancerMetastatic CancerHormone Sensitive Prostate Cancer+1 more
National University Hospital, Singapore 10
Not applicableLooking for participantsNCT07451002
What this trial is testing

Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France

Who this might be right for
Prostatic NeoplasmsMetastatic Hormone-sensitive Prostate Cancer
Janssen Cilag S.A.S. 540
Large-scale testing (Phase 3)Not Yet RecruitingNCT07711002
What this trial is testing

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
AstraZeneca 1,330
Not applicableStudy completedNCT06452212
What this trial is testing

Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Astellas Pharma Korea, Inc. 23
Large-scale testing (Phase 3)Active Not RecruitingNCT05288166
What this trial is testing

Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Who this might be right for
Prostatic NeoplasmsNeoplasm MetastasisUrogenital Neoplasms+14 more
Eli Lilly and Company 925
Testing effectiveness (Phase 2)WithdrawnNCT03343977
What this trial is testing

Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Peng Wang, MD PhD
Testing effectiveness (Phase 2)Study completedNCT06312670
What this trial is testing

Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Prostate CancerProstate Adenocarcinoma
Pedro Barata, MD, MSc 13
Very early researchActive Not RecruitingNCT05683964
What this trial is testing

Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

Who this might be right for
Prostate AdenocarcinomaProstate CancerMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Beth Israel Deaconess Medical Center 9
Early research (Phase 1)Looking for participantsNCT07140900
What this trial is testing

Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Amgen 60
Testing effectiveness (Phase 2)Study completedNCT05059236
What this trial is testing

Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer
Bayer 223
Large-scale testing (Phase 3)Study completedNCT04934722
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Merck Sharp & Dohme LLC 186
Not applicableActive Not RecruitingNCT06019676
What this trial is testing

Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Royal Marsden NHS Foundation Trust 170
Not applicableStudy completedNCT07428642
What this trial is testing

PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.

Who this might be right for
Metastatic Hormone-Sensitive Prostate CancerProstate Cancer
First Affiliated Hospital of Wenzhou Medical University 168
Not applicableStudy completedNCT06072196
What this trial is testing

Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

Who this might be right for
Prostatic Neoplasms
Pfizer 3,017
Testing effectiveness (Phase 2)WithdrawnNCT06392841
What this trial is testing

Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Deleterious HRR Gene MutationBRCA1 Gene Mutation+7 more
Qian Qin
Testing effectiveness (Phase 2)Looking for participantsNCT07650240
What this trial is testing

Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial

Who this might be right for
Recurrent Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8Castration-Sensitive Prostate Cancer+9 more
Mayo Clinic 202
Not applicableLooking for participantsNCT07406282
What this trial is testing

Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

Who this might be right for
Prostatic NeoplasmsMetastatic Hormone-Sensitive Prostate Cancer
Bayer 1,400
Large-scale testing (Phase 3)Study completedNCT04191096
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Merck Sharp & Dohme LLC 1,251
Large-scale testing (Phase 3)Active Not RecruitingNCT02489318
What this trial is testing

Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

Who this might be right for
Prostate Cancer
Aragon Pharmaceuticals, Inc. 1,052
Next Page